Amylyx Pharmaceuticals (NASDAQ:AMLX) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Key Points

• Earnings miss: Amylyx reported GAAP EPS of ($0.37) for the quarter, missing the consensus ($0.34) by $0.03 and the stock traded down on the news.
• LUCIDITY progress and commercialization prep: The company randomized and dosed the final participant in the avexitide LUCIDITY trial with a top‑line readout expected in Q3 2026 and is already drafting NDA sections while launching an expanded access program and citing an estimated U.S. PBH population of ~160,000.
• Balance sheet and spending: Amylyx ended the quarter with $279.8 million in cash and marketable securities, which it says funds a runway into 2028, even as Q1 operating expenses rose to $43.8 million partly due to higher R&D and a $4.0 million milestone payment.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03), FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals' conference call:

• Avexitide LUCIDITY randomized and dosed its last participant in late March and remains on track to complete the 16-week trial with a top-line readout expected in Q3 2026, while NDA sections are already being drafted to support a potential 2027 approval and launch if results are positive.
• The company launched a U.S. expanded access program for up to 250 adults, is initiating a disease‑state education campaign this summer, and cites an independent claims-based market estimate of ~160,000 people in the U.S. with PBH, with endocrinologists showing high intent to treat if an approved therapy becomes available.
• Amylyx reported $279.8 million in cash and marketable securities and says this capital funds an anticipated cash runway into 2028, covering key milestones including the LUCIDITY readout and potential commercialization activities.
• Broader pipeline progress includes IND‑enabling work for the long‑acting GLP‑1 antagonist AMX0318 (targeting a 2027 IND), forthcoming week‑96 data for AMX0035 in Wolfram syndrome, and biomarker data from cohort 1 of the AMX0114 ALS trial expected at an upcoming scientific meeting.
• Q1 operating expenses rose to $43.8 million (up 16% year‑over‑year) driven by higher R&D spend on avexitide and a $4.0 million milestone payment to Gubra, and the company reported slightly higher cash usage this quarter due to that payment and annual bonuses.

Amylyx Pharmaceuticals Price Performance

AMLX traded down $0.86 during trading hours on Thursday, reaching $15.20. 1,451,469 shares of the stock traded hands, compared to its average volume of 1,021,572. The firm's fifty day simple moving average is $15.36 and its two-hundred day simple moving average is $14.26. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -9.81 and a beta of -0.11. Amylyx Pharmaceuticals has a fifty-two week low of $4.20 and a fifty-two week high of $18.60.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on AMLX shares. Bank of America increased their price objective on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Wall Street Zen raised shares of Amylyx Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, March 7th. Mizuho increased their price objective on shares of Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 28th. Guggenheim increased their price objective on shares of Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, March 19th. Finally, HC Wainwright reissued a "buy" rating and issued a $34.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.00.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. acquired a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at $25,000. California State Teachers Retirement System acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at $28,000. Legal & General Group Plc acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at $47,000. BNP Paribas Financial Markets grew its holdings in Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company's stock valued at $47,000 after purchasing an additional 5,904 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Amylyx Pharmaceuticals by 1,116.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company's stock valued at $54,000 after purchasing an additional 4,088 shares in the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.